341 related articles for article (PubMed ID: 27060151)
1. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.
Magrangeas F; Kuiper R; Avet-Loiseau H; Gouraud W; Guérin-Charbonnel C; Ferrer L; Aussem A; Elghazel H; Suhard J; Sakissian H; Attal M; C Munshi N; Sonneveld P; Dumontet C; Moreau P; van Duin M; Campion L; Minvielle S
Clin Cancer Res; 2016 Sep; 22(17):4350-4355. PubMed ID: 27060151
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.
Zhou X; Han S; Cebulla N; Haertle L; Steinhardt MJ; Schirmer D; Runau E; Flamm L; Terhorst C; Jähnel L; Vogt C; Nerreter S; Teufel E; Stanojkovska E; Mersi J; Munawar U; Schindehütte M; Blum R; Reinhold AK; Scherf-Clavel O; Rittner HL; Pham M; Rasche L; Einsele H; Sommer C; Kortüm KM
Biomark Res; 2023 May; 11(1):52. PubMed ID: 37194045
[TBL] [Abstract][Full Text] [Related]
4. Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.
Campo C; Da Silva Filho MI; Weinhold N; Goldschmidt H; Hemminki K; Merz M; Försti A
Neurochem Res; 2017 Mar; 42(3):925-931. PubMed ID: 27422265
[TBL] [Abstract][Full Text] [Related]
5. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.
Zhang Y; Zhang H; Wang J; Wei X; Qu YI; Xu F; Zhang L
Oncol Res; 2024; 32(5):955-963. PubMed ID: 38686049
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Mahmoudpour SH; Bandapalli OR; da Silva Filho MI; Campo C; Hemminki K; Goldschmidt H; Merz M; Försti A
BMC Cancer; 2018 Aug; 18(1):820. PubMed ID: 30111286
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients.
Campo C; da Silva Filho MI; Weinhold N; Mahmoudpour SH; Goldschmidt H; Hemminki K; Merz M; Försti A
Hematol Oncol; 2018 Feb; 36(1):232-237. PubMed ID: 28317148
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
[TBL] [Abstract][Full Text] [Related]
9. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
García-Sanz R; Corchete LA; Alcoceba M; Chillon MC; Jiménez C; Prieto I; García-Álvarez M; Puig N; Rapado I; Barrio S; Oriol A; Blanchard MJ; de la Rubia J; Martínez R; Lahuerta JJ; González Díaz M; Mateos MV; San Miguel JF; Martínez-López J; Sarasquete ME;
Hematol Oncol; 2017 Dec; 35(4):746-751. PubMed ID: 27605156
[TBL] [Abstract][Full Text] [Related]
10. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
Corthals SL; Kuiper R; Johnson DC; Sonneveld P; Hajek R; van der Holt B; Magrangeas F; Goldschmidt H; Morgan GJ; Avet-Loiseau H
Haematologica; 2011 Nov; 96(11):1728-32. PubMed ID: 21791469
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
[No Abstract] [Full Text] [Related]
13. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Kumar SK; Laubach JP; Giove TJ; Quick M; Neuwirth R; Yung G; Rajkumar SV; Richardson PG
Br J Haematol; 2017 Sep; 178(5):756-763. PubMed ID: 28591409
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach.
Yang Y; Zhao B; Lan H; Sun J; Wei G
Crit Rev Oncol Hematol; 2024 May; 197():104353. PubMed ID: 38615869
[TBL] [Abstract][Full Text] [Related]
15. Prediction of bortezomib-induced peripheral neuropathy with the R-R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study.
Nishiwaki U; Yokote T; Hatooka J; Miyoshi T; Iwaki K; Masuda Y; Fujimoto M; Ueda M; Kinoshita Y; Arita Y; Shimizu M; Yamada T; Tanabe K; Akioka T; Imagawa A
Leuk Lymphoma; 2020 Mar; 61(3):707-713. PubMed ID: 31642372
[TBL] [Abstract][Full Text] [Related]
16. [Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Zhang LL; Wang YH; Shao ZH; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):480-484. PubMed ID: 28446297
[TBL] [Abstract][Full Text] [Related]
17. Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.
Cocito F; Ricciardelli G; Mangiacavalli S; Pompa A; Pochintesta L; Ferretti V; Ceccuzzi R; Cazzola M; Bianchi PE; Corso A
Leuk Lymphoma; 2015; 56(12):3440-1. PubMed ID: 25942384
[No Abstract] [Full Text] [Related]
18. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
[TBL] [Abstract][Full Text] [Related]
19. Endometrial vezatin and its association with endometriosis risk.
Holdsworth-Carson SJ; Fung JN; Luong HT; Sapkota Y; Bowdler LM; Wallace L; Teh WT; Powell JE; Girling JE; Healey M; Montgomery GW; Rogers PA
Hum Reprod; 2016 May; 31(5):999-1013. PubMed ID: 27005890
[TBL] [Abstract][Full Text] [Related]
20. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
